NASDAQ:DVAX - Dynavax Technologies Stock Price, Forecast & News

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) released its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.10. The biopharmaceutical company earned $10.58 million during the quarter, compared to analysts' expectations of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The company's revenue for the quarter was up 624.7% compared to the same quarter last year. During the same period last year, the business earned ($0.65) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dynavax Technologies.

5 brokerages have issued 12-month target prices for Dynavax Technologies' stock. Their forecasts range from $13.00 to $20.00. On average, they anticipate Dynavax Technologies' share price to reach $15.33 in the next year. This suggests a possible upside of 189.9% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Media stories about DVAX stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dynavax Technologies earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Array Biopharma (ARRY), Kite Pharma (KITE), Cara Therapeutics (CARA) and Exelixis (EXEL).

Dynavax Technologies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Chicago Capital LLC (4.77%), Rhenman & Partners Asset Management AB (1.29%), California Public Employees Retirement System (0.17%), Alpine Global Management LLC (0.10%) and Patriot Financial Group Insurance Agency LLC (0.01%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Rhenman & Partners Asset Management AB and Patriot Financial Group Insurance Agency LLC. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Alpine Global Management LLC. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $5.29.

Dynavax Technologies has a market capitalization of $443.65 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]